Olon announces HPAPI milestone

Italian CDMO Olon has completed a large-scale high containment production line (OEL < 1 mg/m3) at its Rodano site at a cost of about €10 million. This is part of a planned €27 million it will roll out over 2022-3 that is fully allocated to the expansion of further internal expertise and capacity of high containment production. The new line, which is already operative, enables Olon to produce HPAPIs in batches of 30-250 kg.

“Now we are one of the few CDMO companies to offer the range of specific integrated capabilities necessary to support the customer from the first clinical phase up to industrialisation, regardless of the quantity of product needed and batch size required and regardless of the ongoing molecule development phase,” said CEO Paolo Tubertini. This expansion is also in line with a long-term business strategy of expanding internal technology platforms, focusing on HPAPIs and on biotech.